ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

被引：2
|
作者：
Piotrowska, Z. [1 ]
Ahn, M-J. [2 ]
Pang, Y-K. [3 ]
How, S. H. [4 ]
Sang-We, K. [5 ]
Voon, P. J. [6 ]
Cortinovis, D. L. [7 ]
Carpeno, J. De Castro [8 ]
Tiseo, M. [9 ,10 ]
Abreu, D. Rodriguez [11 ]
Ramalingam, S. S. [12 ]
Li, J. [13 ]
Servidio, L. [13 ]
Sadow, S. [14 ]
Hartmaier, R. J. [15 ]
Cho, B. C. [16 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[2] Sungkyunkwan Univ, Dept Hematol & Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[4] Int Islamic Univ Malaysia, Dept Med, Kulliyyah Med, Kuantan, Malaysia
[5] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Hosp Umum Sarawak, Dept Radiotherapy & Oncol, Kuching, Malaysia
[7] San Gerardo Hosp, Oncol Unit, Monza, Italy
[8] Hosp Univ La Paz, Dept Med Oncol, IdiPAZ, Madrid, Spain
[9] Univ Parma, Dept Med & Surg, Parma, Italy
[10] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[11] Gran Canaria Univ Hosp, Dept Med Oncol, Las Palmas Gran Canaria, Canary Islands, Spain
[12] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[13] AstraZeneca, Oncol Business Unit, Global Med Affairs, Gaithersburg, MD USA
[14] AstraZeneca, Biometr & Informat Sci, Gaithersburg, MD USA
[15] AstraZeneca Oncol R&D, Translat Med, Boston, MA USA
[16] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360P
引用
收藏
页码：S1581 / S1582
页数：2
相关论文
共 50 条
  • [1] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y. K.
    How, S. H.
    Kim, S-W.
    Voon, P. J.
    Cortinovis, D. L.
    De Castro Carpeno, J.
    Tiseo, M.
    Rodriguez Abreu, D.
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1420 - S1421
  • [2] Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
    Ahn, M-J.
    Cho, B. C.
    Pang, Y. K.
    Voon, P. J.
    Kim, S-W.
    De Castro Carpeno, J.
    Tiseo, M.
    Li, J.
    Servidio, L.
    Sadow, S.
    Markovets, A.
    Tang, K. H.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1563 - S1564
  • [3] ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib
    Piotrowska, Z.
    Chmielecki, J.
    Cripps, D.
    Miranda, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S493 - S494
  • [4] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
    Cheng, Y.
    Yu, Y.
    Fan, Y.
    Jiang, L.
    Wu, L.
    Hu, J.
    Wang, J.
    Yao, W.
    Han, Z.
    Yao, Y.
    Fang, J.
    Sun, M.
    Wang, Q.
    Pan, Y.
    Wu, R.
    Liu, J.
    Liu, Y.
    Kulkarni, D.
    Huang, X.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
  • [5] ORCHARD: Osimertinib plus necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
    Riess, J. W.
    De Langen, J. A.
    Piotrowska, Z.
    Goldberg, S. B.
    Goldman, J. W.
    Okamoto, I.
    Ponce Aix, S.
    Teraoka, S.
    Ambrose, H.
    Tang, K. H.
    Maidment, J.
    Ruiz, B. Merchan
    Hewson, N.
    Cosaert, J.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S1571 - S1572
  • [6] Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
    Nieva, J.
    Griesinger, F.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S616 - S617
  • [7] Real-world, first-line Osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y. -H
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 254 - 254
  • [8] FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
    Janne, Pasi A.
    Kobayashi, Kunihiko
    Robichaux, Jacqulyne
    Lee, Chee Khoon
    Sugawara, Shunichi
    Yang, Tsung-Ying
    Kim, Tae Min
    Yanagitani, Noriko
    Kim, Sang-We
    Markovets, Aleksandra
    Bhetariya, Preetida
    Poole, Lynne
    Ghiorghiu, Dana
    Hartmaier, Ryan
    Yang, James Chih-Hsin
    Planchard, David
    CANCER RESEARCH, 2024, 84 (07)
  • [9] Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany
    Griesinger, F.
    Popat, S.
    Okhuoya, P.
    Servidio, L.
    Fonseca, M. J.
    Tolani, E.
    Lu, S.
    Zacharias, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1587
  • [10] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345